| Report | Options implied | Actual move | Market was |
|---|---|---|---|
| April 28, 2026 | ±2.0% | -4.5% | under-priced |
| October 28, 2025 | ±1.3% | +0.7% | over-priced |
| July 31, 2025 | ±1.4% | +10.7% | under-priced |
| April 29, 2025 | ±2.7% | +2.3% | over-priced |
| October 31, 2024 | ±1.4% | -6.5% | under-priced |
| July 30, 2024 | ±2.6% | -5.7% | under-priced |
| May 2, 2024 | ±2.1% | +3.8% | under-priced |
| October 31, 2023 | ±1.9% | +4.8% | under-priced |
| Quarter | EPS (dil.) | Revenue | Net income |
|---|---|---|---|
| Q1 FY2026 | $0.79 | $2.1B | $189M |
| Q4 FY2025 | $1.37 | $2.4B | $333M |
| Q3 FY2025 | $0.93 | $2.3B | $226M |
| Q2 FY2025 | $0.93 | $2.3B | $224M |
Xylem Inc (XYL) reports in 90 days, with the next report estimated for September 11, 2026. Across the last 8 reports, options priced an average ±1.9% earnings move while the stock actually moved 4.9% on average — the market has tended to under-price XYL's earnings risk. Fundamentals into the print: EPS up 14.5% year-over-year, revenue up 2.7%. QuantLogix's live 5-factor engine currently reads XYL as a neutral at 42/100.
Implied move is derived from at-the-money option pricing; actual moves are close-to-close on report days. Next-report dates are estimates until confirmed by the company. Educational market analysis, not investment advice. Browse all signal scorecards →